NASDAQ:EVAX Evaxion Biotech A/S (EVAX) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free EVAX Stock Alerts $4.14 -0.05 (-1.19%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$3.99▼$4.2850-Day Range$2.90▼$4.3152-Week Range$2.82▼$18.50Volume25,022 shsAverage Volume551,731 shsMarket Capitalization$21.61 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Evaxion Biotech A/S alerts: Email Address Evaxion Biotech A/S MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside165.1% Upside$11.00 Price TargetShort InterestHealthy0.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.34Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.19) to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.17 out of 5 starsMedical Sector534th out of 910 stocksBiological Products, Except Diagnostic Industry86th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingEvaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvaxion Biotech A/S has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.82% of the outstanding shares of Evaxion Biotech A/S have been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently decreased by 0.93%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEvaxion Biotech A/S does not currently pay a dividend.Dividend GrowthEvaxion Biotech A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVAX. Previous Next 0.9 News and Social Media Coverage News SentimentEvaxion Biotech A/S has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Evaxion Biotech A/S this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for EVAX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Evaxion Biotech A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.04% of the stock of Evaxion Biotech A/S is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evaxion Biotech A/S are expected to grow in the coming year, from ($0.19) to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion Biotech A/S is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion Biotech A/S is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Evaxion Biotech A/S Stock (NASDAQ:EVAX)Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Read More EVAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVAX Stock News HeadlinesApril 17, 2024 | msn.comEvaxion Biotech A (EVAX) Price Target Decreased by 13.62% to 11.99April 17, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 17, 2024 | finance.yahoo.comEvaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 17, 2024 | globenewswire.comEvaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 17, 2024 | americanbankingnews.comHead-To-Head Survey: Compass Therapeutics (NASDAQ:CMPX) & Evaxion Biotech A/S (NASDAQ:EVAX)April 15, 2024 | americanbankingnews.comHead-To-Head Survey: Evaxion Biotech A/S (NASDAQ:EVAX) versus Jasper Therapeutics (NASDAQ:JSPR)April 3, 2024 | finance.yahoo.comQ4 2023 Evaxion Biotech A/S Earnings Call (Danish)April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 3, 2024 | finance.yahoo.comEvaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call TranscriptApril 2, 2024 | marketwatch.comADRs End Lower; Meta Data Slides 22%April 2, 2024 | globenewswire.comEvaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus InfectionMarch 28, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Business Update and Full Year 2023 Financial ResultsMarch 27, 2024 | investorplace.comEVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023March 27, 2024 | globenewswire.comEvaxion Announces Business Update and Full Year 2023 Financial ResultsMarch 22, 2024 | finance.yahoo.comWhen Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Evaxion Biotech Amid AI-Driven Vaccine Development MilestonesMarch 19, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology PlatformMarch 19, 2024 | globenewswire.comEvaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ PlatformMarch 13, 2024 | msn.comNeuroBo Phase 2a study for MASH drug to proceed as plannedFebruary 29, 2024 | globenewswire.comEvaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology InnovationsFebruary 24, 2024 | msn.comEvaxion Biotech A (EVAX) Price Target Increased by 414.29% to 18.36February 20, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 20, 2024 | finance.yahoo.comEvaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 20, 2024 | globenewswire.comEvaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 12, 2024 | markets.businessinsider.comBuy Rating for Evaxion Biotech: AI Revolutionizing Immunotherapy and Vaccine DevelopmentFebruary 7, 2024 | investing.comEvaxion Biotech AS (EVAX)See More Headlines Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/23/2024Next Earnings (Estimated)5/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EVAX CUSIPN/A CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees63Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$14.00 Low Stock Price Target$8.00 Potential Upside/Downside+165.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($6.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,120,000.00 Net MarginsN/A Pretax Margin-31,390.41% Return on Equity-451.63% Return on Assets-149.27% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$70,000.00 Price / Sales308.73 Cash FlowN/A Price / Cash FlowN/A Book Value($1.17) per share Price / Book-3.54Miscellaneous Outstanding Shares5,220,000Free Float3,043,000Market Cap$21.61 million OptionableOptionable Beta-0.02 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Christian Kanstrup M.Sc. (Age 52)Chief Executive Officer Comp: $373kMr. Andreas Holm Mattsson (Age 48)Co-Founder and Chief AI & Culture Officer Comp: $246kMr. Jesper Nyegaard Nissen M.Sc. (Age 54)Interim CFO & COO Comp: $296kDr. Niels Iversen Moller M.D. (Age 45)Co-Founder, VP of Business & Director Comp: $120kDr. Birgitte Rono Ph.D. (Age 47)Chief Scientific Officer Comp: $336kDr. Jürgen Langhärig EMBAPh.D., Head of Business Development & Member of Advisory BoardMore ExecutivesKey CompetitorsAptose BiosciencesNASDAQ:APTOSurrozenNASDAQ:SRZNPharmaCyte BiotechNASDAQ:PMCBAIM ImmunoTechNYSE:AIMNKGen BiotechNYSE:NKGNView All CompetitorsInstitutional OwnershipLM Advisors LLCBought 337,336 shares on 2/14/2024Ownership: 8.898%View All Institutional Transactions EVAX Stock Analysis - Frequently Asked Questions Should I buy or sell Evaxion Biotech A/S stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVAX shares. View EVAX analyst ratings or view top-rated stocks. What is Evaxion Biotech A/S's stock price target for 2024? 2 equities research analysts have issued 12 month price targets for Evaxion Biotech A/S's stock. Their EVAX share price targets range from $8.00 to $14.00. On average, they anticipate the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 165.1% from the stock's current price. View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts. How have EVAX shares performed in 2024? Evaxion Biotech A/S's stock was trading at $6.8570 at the start of the year. Since then, EVAX stock has decreased by 39.5% and is now trading at $4.15. View the best growth stocks for 2024 here. When is Evaxion Biotech A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 29th 2024. View our EVAX earnings forecast. How were Evaxion Biotech A/S's earnings last quarter? Evaxion Biotech A/S (NASDAQ:EVAX) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $0.07 million for the quarter. When did Evaxion Biotech A/S's stock split? Evaxion Biotech A/S shares reverse split on the morning of Monday, January 22nd 2024. The 1-10 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Evaxion Biotech A/S IPO? Evaxion Biotech A/S (EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Evaxion Biotech A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVAX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
